EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker

Márcio Galindo Kiuchi, Shaojie Chen, Neil Alexander Hoye, Helmut Pürerfellner

Journal of Interventional Cardiac Electrophysiology · 2018-01 · 51 (1) · 51-59

DOI: 10.1007/s10840-017-0302-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Interventional Cardiac Electrophysiology, online erschienen am 20.12.2017. Verfasst von Márcio Galindo Kiuchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Artificial Cardiac Stimulation and Electrophysiology, Cardiostim, Rua Dr. Celestino, 122-1103-Centro, Niterói, RJ, 24020-091, Brazil. m…. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Health plans in the state of Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atrial fibrillation (AF) commonly occurs in chronic kidney disease (CKD), occasioning adverse outcomes. Merging pulmonary vein isolation (PVI) and renal sympathetic denervation (RSD) may decrease the recurrence of AF in subjects with CKD and uncontrolled hypertension. We considered that RSD could reduce the recurrence of AF in patients with CKD by modulating sympathetic hyperactivity. We aimed to evaluate the impact of RSD or spironolactone 50 mg/day associated with PVI in reducing systolic blood pressure (BP), AF recurrence, and AF burden in patients with a history of paroxysmal AF and mild CKD. METHODS: This was a single-center, prospective, longitudinal, randomized, double-blind study. The individuals were randomly divided into two groups (PVI + spironolactone, n = 36, and PVI + RSD, n = 33). All of them were followed for exactly 1 year to assess maintenance of sinus rhythm and to monitor the other variables. RESULTS: Ambulatory BP measurements were reduced in both groups and at the 12th month also differed between groups. Significantly more patients in the PVI + RSD (61%) than in the PVI + spironolactone group (36%) were AF-free at the 12th month of follow-up, P = 0.0242. Toward the end of the study, the mean AF burden was lower in the PVI + RSD group as compared to PVI + spironolactone group, at the 9th month: ∆ = - 10% (P < 0.0001), and at the 12th month: ∆ = - 12% (P < 0.0001), respectively. CONCLUSIONS: PVI + RSD is safe and appears to be superior to PVI + spironolactone in BP reduction, augmentation of AF event-free rate, reduction of AF burden, and improvement of renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAtrial FibrillationCatheter AblationCombined Modality TherapyDouble-Blind MethodEchocardiographyElectrocardiographyFemaleHumansHypertensionKaplan-Meier EstimateLongitudinal StudiesMaleMiddle AgedNormal DistributionPacemaker, ArtificialPilot ProjectsPrognosisProspective StudiesPulmonary Veins

Stichwörter der Autor:innen

Atrial fibrillationChronic kidney diseaseHypertensionPacemakerPulmonary vein isolationRenal sympathetic denervationSympathetic hyperactivity

Substanzen

Spironolactone

Autor:innen und Institutionen

  • Department of Artificial Cardiac Stimulation and Electrophysiology, Cardiostim, Rua Dr. Celestino, 122-1103-Centro, Niterói, RJ, 24020-091, Brazil. marciokiuchi@gmail.com.
  • Department of Cardiology, Elisabethinen University Teaching Hospital Linz, Linz, Austria. marciokiuchi@gmail.com.
  • Department of Cardiology, Elisabethinen University Teaching Hospital Linz, Linz, Austria.
  • Department of Cardiology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Renal Medicine, St James's University Hospital, Leeds, UK.

Förderung

  • Health plans in the state of Rio de Janeiro

Zitieren

APA

Kiuchi, M. G., Chen, S., Hoye, N. A., & Pürerfellner, H. (2018). Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. Journal of Interventional Cardiac Electrophysiology, 51(1), 51-59. https://doi.org/10.1007/s10840-017-0302-2

Vancouver

Kiuchi MG, Chen S, Hoye NA, Pürerfellner H. Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker. Journal of Interventional Cardiac Electrophysiology. 2018;51(1):51-59. doi:10.1007/s10840-017-0302-2

BibTeX
@article{Kiuchi2018,
  author = {Kiuchi, Márcio Galindo and Chen, Shaojie and Hoye, Neil Alexander and Pürerfellner, Helmut},
  title = {Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker},
  journal = {Journal of Interventional Cardiac Electrophysiology},
  year = {2018},
  volume = {51},
  number = {1},
  pages = {51--59},
  doi = {10.1007/s10840-017-0302-2}
}
Kostenlos starten →